Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.NICE recommends MSD’s pembrolizumab to treat melanoma
The latest announcement is expected to be beneficial for nearly 1,500 people aged 12 years and above with melanoma. This drug is said to be the first NICE-recommended
The latest announcement is expected to be beneficial for nearly 1,500 people aged 12 years and above with melanoma. This drug is said to be the first NICE-recommended
A PARP inhibitor, Lynparza is the first targeted treatment, which is designed to inhibit DNA damage response (DDR) in cells/tumours which harbour deficiency in homologous recombination repair (HRR),
Retevmo (selpercatinib, 40 mg & 80 mg capsules) is indicated to treat locally advanced or metastatic solid tumours in adult patients with a rearranged during transfection (RET) gene
Amvuttra targets and supresses specific messenger RNA (mRNA) that blocks the wild-type and variant transthyretin (TTR) protein production before it is made. It uses the company’s Enhanced Stabilization
As part of the partnership deal, the entities will initially plan to conduct a preclinical proof-of-concept efficacy study with the new radio-conjugate targeting Netrin-1, combining Netris’ NP137 with
The company is seeking approval for tukysa and trastuzumab combination for the treatment of HER2-positive colorectal cancer in adult patients who have received at least one treatment regimen
Yescarta is a chimeric antigen receptor (CAR) T-cell therapy that is indicated to treat diffuse large B-cell lymphoma (DLBCL) and high-grade B-cell lymphoma (HGBL) in adult patients whose
Under the deal terms, NeuroBo will undertake the development, regulatory and commercial works for the two therapies across the world excluding certain Asian-Pacific areas. Dong-A will be responsible
Terlivaz is claimed to be the first and only FDA-approved product that is indicated for improving kidney function in HRS adult patients with quick kidney function reduction. The
Established in January 2011, IMN is a joint research unit of the University of Bordeaux and the French National Centre of Scientific Research (CNRS). The collaboration will focus